Compensation Overview

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit frontier targets in RAS-addicted cancers.  The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. As a new member of the Revolution Medicines team, you will join other outstanding scientists in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

The Opportunity:

As a key member of a cross-functional Cancer Pharmacology team, you will report into Executive Director and Head of Cancer Pharmacology in Translational Research.

• Be a critical contributor and provide strong strategic and technical leadership in translation research group and multi-disciplinary research and development project teams with a focus on preclinical modeling of novel combinations and resistance with an indication lens.

• Coordinate internal efforts and external contract research organization to execute translational studies for cross-functional teams; manage priorities and timelines in a fast-paced research environment.

• Take a leadership role across different projects in a matrix environment, have the ability to serve as a functional rep in key project teams.

• Manage and analyze experimental data and present results at internal meetings and scientific conferences.

• Develop high-quality protocols and outputs and maintain detailed documentation of procedures and data to comply with internal standard operating procedures and other quality criteria, where necessary.

Required Skills, Experience and Education:

• Ph.D. in pharmacology, oncology, cell biology or a related discipline, with 2-5 years of post-doctoral and at least 5 years of relevant industry experience in cancer drug discovery and development.

• Strategic thinker with proven leadership skills, prior project team leadership roles would be an advantage.

• Deep expertise in cancer pharmacology and oncogenic signaling pathways desired.

• Rigorous, quantitative and detail-oriented experimentalist.

• Demonstrated ability to multi-task, prioritize options, anticipate challenges, and execute on goals as a member of an interdisciplinary team is extremely important.

• Excellent written and verbal communication skills.

• Thrives in a collaborative team setting and is driven by a desire to be innovative in a high energy, small company environment.

Preferred Skills:

• Experience working with external collaborators on both preclinical animal studies and ex vivo PD assays is preferred.

• Strong track record of scientific productivity as evidenced by high-quality, impactful publications.

The base salary range for this full-time position is $160,000 to $200,000 for candidates based at our headquarters in Redwood City, CA. The range displayed on each job posting is intended to be the minimum and maximum salary for the position in Redwood City and will be adjusted for the local market a candidate is based. Our salary ranges are determined by role, level, and location. Individual pay is determined by multiple factors, including job-related skills, experience, market dynamics, and relevant education or training.

Please note that base salary is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.

Revolution Medicines is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital status, medical condition, and veteran status.

Revolution Medicines takes protection and security of personal data very seriously and respects your right to privacy while using our website and when contacting us by email or phone. We will only collect, process and use any personal data that you provide to us in accordance with our CCPA Notice and Privacy Policy. For additional information, please contact [email protected].

#LI-Hybrid  #LI-LN1